EVALUATION OF THE CUTANEOUES LEISHMANIASIS TREATMENT IN AL-MERGHEB, LIBYA
الملخص
Cutaneous leishmaniasis (CL) is a parasitic disease which endemic in the Mediterranean region, including Libya, and it is considered as main public health problem. Treatment of CL now a day's become a challenge to the scientists over the world. Pentostam has clinical efficacy against CL. Because of the limited data on the treatments used for CL in addition to undesirable side effects, there has been a demand for alternative therapies for CL. The objective of this study to evaluate the efficacy of the used remedy regime to treat the CL patients in Libya. We found that local and systemic pentostam for CL are useful and well tolerated. Combination of local pentostam and cryotherapy improve the chances that lesions will heal more rapidly. Because some of CL lesions heal spontaneously without treatment, decisions regarding additional therapy that heal lesions faster and prevent relapse must take into account. Therefore, we believe that further clinical studies should be conducted with cryotherapy in combination with other local medication.
المراجع
-Abdellatif, M Z M, El-Mabrouk, K and Ewis, A A. (2013): An epidemiological study of cutaneous leishmaniasis in Al-Jabal Al-Gharbi, Libya. Korean J. Parasitol :51(1) pp75-84.
-Abdulrahman A. Alrajhi, M.D., M.P,H., Elfaki A. Ibrahim, PH.D., Edward B. De Vol, PH.D., Mohammad Khairat, M.D., Rajab M. Faris, M.D., and James H. Maguire, M.D., M.P.H. (2002): Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania major. N Engl J Med, Vol. 346, No. 12
-Ahmed Sabra M. and Hala H. Abou faddan. (2013): Cutaneous Leishmaniasis in Gharyan -Libya – a Case - Control Study. Life Science Journal 2013;10(1).
-Alrajhi AA, Ibrahim EA, de Vol EB, Khairat M, Faris RM, Maguire JH. (2002): Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania major. New England Journal of Medicine 2002; Vol. 346, issue 12:891–5.
-Amro A, Gashout A, Al-Dwibe H, Zahangir Alam M, and Annajar B, (2012): First Molecular Epidemiological Study of Cutaneous Leishmaniasis in Libya. PLoS Negl Trop Dis 6(6): e1700. doi:10.1371/journal.pntd.0001700.
-El-Buni A, Jabeal I and Ben-Darif A (2000): Cutaneous leishmaniasis in the Libyan Arab Jamahiriya a study of the Yafran area. East Mediterr Health J 6: 884–887.
-Escobar, M A, Martinez F, Scott Smith D, Palma G I. (1992): American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop Doct. 22:69-78.
-Faghihi G, Tavakoli-kia R. (2003): Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol. 2003 Jan;28(1):13-6.
-Glenn Wortmann, Michael Zapor, Roseanne Ressner, Susan Fraser, Josh Hartzell, Joseph Pierson, Amy Weintrob, and Alan Magill. (2010): Liposomal Amphotericin B for treatment of Cutaneous Leishmaniasis. Am.J.Trop.Med.Hyg.,83(5),pp.1028-1033
-González U, Pinart M, Reveiz L, Alvar J. (2008): Interventions for OldWorld cutaneous leishmaniasis (Review). The Cochrane Library. Issue 4
-Hepburn NC. (2000): Cutaneous leishmaniasis. Clin Exp Dermatol 25: 363–370.
-Herwaldt BL. (1999): Leishmaniasis. Lancet,. 354:1191-1199.
-Khatami A, Firooz A, Gorouhi F, Dowlati Y. (2007): Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57: 335.
-Layegh Pouran, Fakhrozaman Pezeshkpoor, Amir Hossein Soruri, Parisa Naviafar, and Toktam Moghiman. (2009): Efficacy of Cryotherapy versus Intralesional Meglumine Antimoniate (Glucantime) for Treatment of Cutaneous Leishmaniasis in Children. Am. J. Trop. Med. Hyg., 80(2), pp. 172–175.
-Lopez, Liliana , Cruz, Claudia, Godoy, Gonzalo, Robledo, Sara M and Velez, Ivan D. (2013): Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. Rev. Inst. Med. Trop. Sao. Paulo. 55(3): pp.197-204.
-Markle WH,Makhoul K. (2004): Cutaneous leishmaniasis: recognition and treatment. American Family Physician 2004;69(6):1455–60.
-Mengistu G, Laskay T, Gemetchu T, Humber D, Ersamo M, Evans D, et al. (1992): Cutaneous leishmaniasis in south-western Ethiopia: Ocholo revisited. Trans R Soc Trop Med Hyg. 86:149–53.
-Reithinger R, Dujardin JC, Louzir H, Pirmez C. and Alexander B. (2007): Cutaneous leishmaniasis. Lancet Infectious Diseases 7: 581–596.
-Richard Reithinger, Jean-Claude Dujardin, Hechmi Louzir, Claude Pirmez, Bruce Alexander, Simon Brooker. (2007): Cutaneous Leishmaniasis. The Lancet Infectious Diseases, Vol 7.
-Sharifi I, Fekri AR, Aflattonian MR, Nadim A, Nikian Y, Kamesipour A. (1998): Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994–95. Bull World Health Organ 76: 289–293.
-Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. (1998): Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmani-asis in Bam, Iran. Lancet 1998; 351:1540-3.
-Sharma NL, Mahajan VK, Kanga A, Sood A, Katoch VM, Mauricio I, et al. (2005): Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary fi ndings of the study of 161 new cases from a new endemic focus in Himachal Pradesh, India. Am J Trop Med Hyg. 2005;72:819–24.
-Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. (1996): Treatment of kala-azar with oral fluconazole. Lancet; 348:614
-Talari SA, Talaei R, Shajari GR, Vakili Z, Taghaviardakani A. (2006): Childhood cutaneous leishmaniasis: report of 117 cases from Iran. Korean J Parasitol 44: 355–360.
-The world health report (1996): fighting disease, fostering development. Geneva: World Health Organization :50
-Torrus D, Boix V, Massa B, Portilla J, Perez-Mateo M. (1996): Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother; 37:1042-3
-Uzun S: Leishmaniasis. Dermatology. Ed. Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL. (2008). 3rd edition, Istanbul, Nobel Tıp Kitabevi, 659-682.
-Yazdi C., M Narmani, B Sadri. (2002): Cutaneous Leishmaniasis in Iran. The Internet Journal of Infectious Disease Volume 3Number. P1-5.
-William H. Markle, M.D., and Khaldoun Makhoul., M.D. (2004): Cutaneous Leishmaniasis: Recognition and treatment. American Family Physician., Vol 69, No. 6
-World Health Organization (2014): WHO Regional Publications, Eastern. Mediterranean Series. Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region.
-Wortmann Glenn, Michael Zapor, Roseanne Ressner, Susan Fraser, Josh Hartzell, Joseph Pierson, Amy Weintrob and Alan Magill (2010): Lipsosomal Amphotericin B for Treatment of Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2010 Nov;83(5):1028-33. doi: 10.4269/ajtmh. 2010.10-0171.
التنزيلات
منشور
كيفية الاقتباس
إصدار
القسم
الرخصة
الحقوق الفكرية (c) 2017 Nouara Elazirg Elammari1، Salem Ramadan Sariti2، Juima Mohamed Saleh Elhadar، Fathiya A. A. Asteal4
هذا العمل مرخص بموجب Creative Commons Attribution 4.0 International License.
